These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22242557)

  • 1. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
    Gontarewicz A; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
    Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
    J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENMD-2076 for hematological malignancies.
    How J; Yee K
    Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
    Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
    Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
    Steeghs N; Mathijssen RH; Wessels JA; de Graan AJ; van der Straaten T; Mariani M; Laffranchi B; Comis S; de Jonge MJ; Gelderblom H; Guchelaar HJ
    Invest New Drugs; 2011 Oct; 29(5):953-62. PubMed ID: 20182906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
    Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
    Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinases as anticancer drug targets.
    Gautschi O; Heighway J; Mack PC; Purnell PR; Lara PN; Gandara DR
    Clin Cancer Res; 2008 Mar; 14(6):1639-48. PubMed ID: 18347165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora kinase inhibitors.
    Kitzen JJ; de Jonge MJ; Verweij J
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
    Kimura S
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1442-9. PubMed ID: 21154126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
    Cheung CH; Coumar MS; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinases as targets for cancer therapy.
    Mountzios G; Terpos E; Dimopoulos MA
    Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase inhibitors as anticancer molecules.
    Katayama H; Sen S
    Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
    Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
    Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.